Journal of the National Cancer Institute Advance Access originally published online on May 26, 2009
JNCI Journal of the National Cancer Institute 2009 101(11):774-775; doi:10.1093/jnci/djp152
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2009.
NEWS |
Cervical Cancer: The Second-Generation Vaccines Move Forward
| The first 10% of the full text of this article appears below. |
The quadrivalent human papillomavirus (HPV) vaccine is nearly 100% effective at protecting against precancerous cervical lesions caused by the HPV types included in the vaccine, which was approved by the U.S. Food and Drug Administration in 2006. But experts agree that both the quadrivalent vaccine (Gardasil) —and a bivalent vaccine approved in Europe and elsewhere that relies on similar technology (Cervarix)—fall short on two counts: cost and protection against the less common cancer-causing HPV strains.
"Eighty percent of cervical cancer occurs in the developing world where they cannot afford even a vaccine that costs $10, let alone one that costs $120," said John Schiller, Ph.D., a senior investigator at the National Cancer Institute and coinventor of the strategy used to create the current vaccines. "They are going to need a vaccine that costs $1 or $2 per dose to have sustainable
More Strategies